IHH Healthcare Bhd (5225) fair value: what the stock is really worth
We calculate from audited financials what IHH Healthcare Bhd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch IHH Healthcare Bhd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services.
Show more
IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services. The company also offers secondary care facilities, including medical emergencies and acute treatment, as well as specialist consultation, diagnostics, and lab services; tertiary care services comprising specialist consultative care, advanced treatment, complex surgery, and inpatient care services; and quaternary care services, such as organ transplants, neurosurgery, cardiac surgery, and reconstructive plastic surgery. In addition, it provides ancillary services, including diagnostics, laboratory testing, radiology, physiotherapy, and integrated rehabilitation and advanced molecular diagnostics services. Further, the company offers medical education; train and develop nurses, doctors, clinicians, and allied healthcare professionals; administrative, management, consultancy services; emergency, home, and ambulatory care services; healthcare information systems, web-based applications, and other technology solutions; and real estate investment trust services. Additionally, it provides services for medical diagnostic laboratory tests; develops, constructs, and leases medical facility buildings and healthcare facilities; provides catering, laundry, and cleaning services for hospitals; and haemodialysis services, as well as imports and wholesales drug and medical materials. The company engages in the letting of properties; and computer software designing, development, customization, integration, implementation, maintenance, and related services. IHH Healthcare Berhad was incorporated in 2010 and is based in Kuala Lumpur, Malaysia.
Stock analysis
IHH Healthcare Bhd (5225) currently trades at 7.64 MYR, while our model-based Fair Value estimate is 4.61 MYR, implying the stock looks roughly 65.7% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 4.87 MYR per share, and 2 of the 26 models we run sit above the 7.64 MYR price.
Bear case: the Dividend Discount group reads lowest at 1.69 MYR, and 24 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: 2.37 MYR (bear) to 6.33 MYR (bull), the price of 7.64 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
IHH Healthcare Bhd reported revenue of 25.7B MYR in FY2025 versus 17.1B MYR in FY2021, a compound +10.7%/yr. Reported net income was 2.1B MYR in FY2025, compounding +3.1%/yr from FY2021.
Key figures
Market cap 75.1B MYR (≈ $18.4B) · P/E ratio 31.8 · P/S ratio 2.60 · EPS (TTM) 0.2400 MYR · Dividend yield 1.4% · Net margin 8.2% · Return on equity 7.9% · Return on assets (EBIT) 6.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −40%, 5225 screens richer than that median.
Fair Value models
Bear 2.37 MYRFair Value 4.61 MYRBull 6.33 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0980 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+31.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+30.5%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.31% vs 10%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.6%
Yearly sales growth analysts expect, extended to five years.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 256 stocks
Beats the industry median on 7/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−42% · Bottom 25%
Profitability
Return on equity (TTM)8% · Above median
Return on assets4% · Above median
Net margin (TTM)8% · Above median
Operating margin (TTM)15% · Above median
Growth and dividend
Revenue growth4% · Below median
Dividend yield (TTM)1.4% · Below median
Balance sheet
Debt / equity0.26× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)31.8× · Pricier than median
P/B0.61× · Cheapest 25%
P/S (TTM)0.72× · Cheaper than median
P/FCF11.6× · Priciest 25%
EV/EBITDA4.6× · Cheapest 25%
PEG4.09× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)21· sector 27
PAST (return on equity)32· sector 31
HEALTH (low debt)87· sector 90
DIVIDEND (yield)27· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "IHH Healthcare Bhd Fair Value". https://www.fairvalue-calculator.com/stock/5225
Frequently asked questions
Is IHH Healthcare Bhd (5225) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of 4.61 MYR versus a price of 7.64 MYR, about −40% upside (overvalued).
What is the fair value of 5225?
Our model-based fair value for IHH Healthcare Bhd is 4.61 MYR (as of Sep 18, 2026), built from audited fundamentals. The current price: 7.64 MYR.
What is the quality score of 5225?
IHH Healthcare Bhd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IHH Healthcare Bhd (5225)?
Our model-based price target is the fair value of 4.61 MYR (as of Sep 18, 2026) from 26 valuation models. Cautious scenario 2.37 MYR, optimistic scenario 6.33 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the IHH Healthcare Bhd stock forecast for 2026?
Our models put fair value at 4.61 MYR, about −40% upside versus a price of 7.64 MYR (overvalued). Cautious scenario 2.37 MYR, optimistic scenario 6.33 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of IHH Healthcare Bhd (5225)?
IHH Healthcare Bhd reported trailing-twelve-month revenue of about 26.0B MYR (latest available figure, as of Sep 18, 2026).
Does IHH Healthcare Bhd pay a dividend?
IHH Healthcare Bhd currently shows a dividend yield of about 1.37% relative to its recent price (as of Sep 18, 2026).
What growth is priced into IHH Healthcare Bhd (5225)?
For today's price to be fair in a discounted-cash-flow model, IHH Healthcare Bhd would have to grow free cash flow by +25.0 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.0 % per year. As of Sep 18, 2026.
What discount rate (WACC) does the fair value of 5225 use?
Our models discount IHH Healthcare Bhd at 9.2 %: a base by market capitalisation (large), damped by beta 0.13, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For IHH Healthcare Bhd that is +25.0 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has IHH Healthcare Bhd (5225) delivered so far?
Over the past 5 years revenue at IHH Healthcare Bhd grew +14.0 % a year. The price currently implies +25.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of IHH Healthcare Bhd (5225) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into IHH Healthcare Bhd (+25.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of IHH Healthcare Bhd (5225)?
The free-cash-flow yield on the price is 2.38 %: that much free cash flow IHH Healthcare Bhd produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of IHH Healthcare Bhd (5225)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IHH Healthcare Bhd it is 4.61 MYR per share (as of Sep 18, 2026), against a price of 7.64 MYR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is IHH Healthcare Bhd stock overvalued or undervalued in 2026?
As of Sep 18, 2026, 5225 trades above its calculated fair value: price 7.64 MYR, fair value 4.61 MYR, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5225?
No. The price is what the market pays today (7.64 MYR); the fair value is what the company's own numbers justify (4.61 MYR). For IHH Healthcare Bhd the two are 3.03 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is IHH Healthcare Bhd worth?
The market values IHH Healthcare Bhd at about 75.1B MYR (market capitalisation, as of Sep 18, 2026). Per share that is 7.64 MYR; our models calculate a fair value of 4.61 MYR per share.
What do the bullish and bearish scenarios say about 5225?
Our models span a range for IHH Healthcare Bhd: cautious scenario 2.37 MYR, base 4.61 MYR, optimistic 6.33 MYR per share (as of Sep 18, 2026, price 7.64 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 5225?
IHH Healthcare Bhd trades at a price-to-earnings ratio of 31.8 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4.61 MYR is built from several models across several years. Other multiples: PEG 4.1, P/B 0.6, P/S 0.7, EV/EBITDA 4.6.
What is the PEG ratio of 5225?
The PEG ratio of IHH Healthcare Bhd is 4.09 (P/E divided by earnings growth, as of Sep 18, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of IHH Healthcare Bhd (5225)?
Balance-sheet figures for IHH Healthcare Bhd (as of Sep 18, 2026): return on equity 7.9%, debt of 0.26 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 5225 from its 52-week high?
IHH Healthcare Bhd trades at 7.64 MYR, about 27% below its 52-week high of 10.42 MYR and 21% above the low of 6.34 MYR (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of 4.61 MYR is for.
Which stocks are comparable to IHH Healthcare Bhd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IHH Healthcare Bhd stock attractive at the current price?
The data as of Sep 18, 2026: price 7.64 MYR, calculated fair value 4.61 MYR (−40%), Quality Score 50/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5225 calculated?
We run IHH Healthcare Bhd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.61 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. IHH Healthcare Bhd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IHH Healthcare Bhd (5225)?
The closing price on Sep 18, 2026 was 7.64 MYR. Our model-based fair value is 4.61 MYR, about −40% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IHH Healthcare Bhd right now?
The price sits above even our optimistic bull case (6.33 MYR). The favourable scenario is already priced in. The model range is unusually wide (2.37 MYR to 6.33 MYR). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of IHH Healthcare Bhd (5225) come from?
Earnings per share at IHH Healthcare Bhd grew +13.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.0 %, EBIT margin +0.0 %, tax rate +0.4 %, residual (interest, one-offs) +1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of IHH Healthcare Bhd
How large is the market capitalisation of IHH Healthcare Bhd (5225)?
The market capitalisation of IHH Healthcare Bhd is 75.1B MYR (≈ $18.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IHH Healthcare Bhd (5225)?
The price-to-sales ratio of IHH Healthcare Bhd is 2.60 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IHH Healthcare Bhd (5225)?
Earnings per share at IHH Healthcare Bhd are 0.2400 MYR (price ÷ EPS = P/E 31.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of IHH Healthcare Bhd (5225)?
The dividend yield of IHH Healthcare Bhd is 1.4% (payout 43.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of IHH Healthcare Bhd (5225)?
The net margin of IHH Healthcare Bhd is 8.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IHH Healthcare Bhd (5225)?
The return on equity (ROE) of IHH Healthcare Bhd is 7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IHH Healthcare Bhd (5225)?
On an EBIT basis the return on assets of IHH Healthcare Bhd is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IHH Healthcare Bhd (5225)?
The operating margin of IHH Healthcare Bhd is 14.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IHH Healthcare Bhd (5225)?
Revenue at IHH Healthcare Bhd is growing +4.1% versus a year earlier (3y avg +12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at IHH Healthcare Bhd (5225)?
Earnings per share at IHH Healthcare Bhd are growing +2.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does IHH Healthcare Bhd (5225) carry?
The net debt of IHH Healthcare Bhd is 15.9B MYR (fiscal year 2025, ≈ 9.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch IHH Healthcare Bhd in the live analysis
One click puts IHH Healthcare Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
